Compounded
Tirzepatide
Our most powerful weight-loss option. The dual GIP/GLP-1 agonist in Mounjaro® and Zepbound® — proven to reduce body weight by an average of 22.5% at 72 weeks in the SURMOUNT-1 trial.
What is Tirzepatide?
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist — a medication that simultaneously activates two different gut hormone receptors involved in appetite, metabolism, and insulin regulation. It was developed by Eli Lilly and FDA-approved as Mounjaro® (for type 2 diabetes, 2022) and Zepbound® (for chronic weight management, 2023).
By targeting both the GLP-1 and GIP pathways, tirzepatide produces stronger appetite suppression and metabolic effects than GLP-1–only medications — making it the most effective pharmacological weight-loss agent currently available.
Drug class
Dual GIP/GLP-1 receptor agonist
Original brand
Mounjaro® / Zepbound® (Eli Lilly)
Administration
Once-weekly subcutaneous injection
How Tirzepatide Works
Tirzepatide's dual-receptor mechanism is what sets it apart — activating both GLP-1 and GIP pathways produces synergistic effects greater than either pathway alone.
- Suppresses appetite via hypothalamus
- Slows gastric emptying (prolongs satiety)
- Reduces food cravings and reward-driven eating
- Improves insulin secretion after meals
- Enhances fat metabolism and energy expenditure
- Potentiates GLP-1 effects on appetite
- Improves glucose metabolism
- May reduce GLP-1 side effects (nausea)
The result: more powerful hunger suppression, greater metabolic benefits, and superior weight loss outcomes compared to GLP-1–only therapy.
Dosing Schedule
Tirzepatide starts at a low dose and escalates gradually over 20 weeks to the maintenance dose, minimizing side effects while building to full therapeutic effect.
Initiation dose — lowest effective dose for tolerance
First escalation — significant appetite reduction begins
Therapeutic range for many patients
Continued escalation if tolerated
High therapeutic dose
Maximum dose — per provider discretion
* Dosing is individualized. Your prescribing provider may adjust based on your response, tolerability, and weight-loss goals.
Common Side Effects
Tirzepatide's side effect profile is similar to semaglutide — primarily gastrointestinal and typically mild-to-moderate during dose escalation.
Most Common (≥10% of patients)
Nausea
Tip: Most common during escalation; eat smaller portions and avoid fatty foods
Diarrhea
Tip: Usually transient; stay well-hydrated
Constipation
Tip: Increase fiber intake; adequate hydration helps
Vomiting
Tip: Contact care team if persistent or severe
Less Common — Seek Care If Severe
Abdominal pain
Severe or persistent pain warrants immediate evaluation
Decreased appetite / fatigue
Monitor nutrition; ensure adequate caloric intake
Injection site reactions
Redness or swelling; rotate injection sites each week
Heart rate changes
Inform your provider of any palpitations
Clinical Results
Tirzepatide's efficacy is supported by the landmark SURMOUNT clinical trial program — the most impressive weight-loss results ever recorded in a pharmaceutical trial.
22.5%
Mean body weight reduction
SURMOUNT-1 at 72 weeks (15 mg group)
91%
Lost ≥5% body weight
vs. 35% with placebo
2,539
Participants in SURMOUNT-1
Adults with obesity or overweight + comorbidity
Tirzepatide vs. Semaglutide — Weight Loss Comparison
SURMOUNT-1 Trial Summary
Published in the New England Journal of Medicine (2022), the SURMOUNT-1 trial was a 72-week, randomized, double-blind, placebo-controlled trial of 2,539 adults with obesity (BMI ≥30) or overweight with weight-related comorbidities. Participants received tirzepatide 5 mg, 10 mg, or 15 mg weekly. The highest-dose group (15 mg) achieved a mean weight reduction of 22.5% — the greatest weight loss ever demonstrated in a randomized pharmaceutical trial. Over 91% of tirzepatide participants lost ≥5% body weight vs. 35% in the placebo group.
Reference: Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
Injection Site Guide
Tirzepatide is administered as a once-weekly subcutaneous injection. Rotating sites prevents tissue irritation and ensures consistent absorption.
Abdomen
Preferred site. Inject at least 2 inches from navel. Easiest for self-administration.
Outer Thigh
Front of thigh, midway between knee and hip. Good alternative to abdomen.
Upper Arm
Outer aspect only. May require assistance. Slightly less predictable absorption.
Rotate injection sites weekly. Do not inject into skin that is tender, bruised, scarred, or hardened. Step-by-step video instructions are provided to all patients.
Starting at $199/month
Everything included — consultation, dual-action medication, supplies, and ongoing provider support.
Dramatically less than brand-name Zepbound® ($1,200–1,500+/mo). No hidden fees. Cancel anytime.
*Results not guaranteed. Provider consultation required. Compounded medications are not FDA-approved; active ingredients are FDA-approved.
Tirzepatide Questions Answered
What is compounded tirzepatide?
How is tirzepatide different from semaglutide?
How quickly will I see results with tirzepatide?
What side effects should I expect?
Is tirzepatide safe if I have type 2 diabetes?
Who is tirzepatide most suitable for?
Not sure which medication is right for you?
Our licensed providers will review your health profile and recommend semaglutide or tirzepatide based on your specific goals and medical history.